TY - JOUR T1 - Intratumoral Hyperthermic Chemotherapy Injection in Peripheral Non-Small Cell Lung Cancer; a Pilot Study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.5124 VL - 56 IS - suppl 64 SP - 5124 AU - Mohamed Tohlob AU - Lucy Suliman AU - Ahmed Elmorsy AU - Mohamed Ibrahim AU - Asem Hewidy Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/5124.abstract N2 - Assess efficacy &safety of transthoracic injection of hyperthermic chemotherapy with systemic chemotherapy in inoperable NSCLCMethods: Randomized clinical trial,done at Chest department&Oncology center, Mansoura, Egypt, 2017 -2019. 30 patients with peripheral NSCLC not candidate for surgery randomly divided into 3 groups: A 10 patients subjected to intratumoral injection of hyperthermic cisplatin at 40°-45°C plus systemic chemotherapy, B 10 patients subjected to intratumoral injection of cisplatin at room temperature 20°-25°C plus systemic chemotherapy and C 10 patients were treated with systemic chemotherapy. Patients who were operable, hypersensitive to cisplatin were excluded. Primary end points were quality of life and radiological response. Secondary end point was survival.Results: Statistically significant improvement in quality of life in group A&B but decreased in group C after 6 months. Radiology after 6 months in group A, 1 patient had complete response, 6 patients had partial response, 1 patient stable response and 2 patients had progression. As regard group B, 6 patients had partial response, 2 patients had stable response and 2 patients had progression. As regard group C 7 patients had progression, 2 patients had partial response and one patient had stable response. There were few immediate controllable complications, systemic complications were low in group A&B than group C. Median survival in group A was 16 months, in group B was 15 months and was 8 months in group C.Conclusion: Intratumoral hyperthermic chemotherapy is promising effective, safe and inexpensive palliative treatment for patients with inoperable peripheral NSCLC.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 5124.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -